Stockreport

Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business Results

Protalix BioTherapeutics, Inc. (DE)  (PLX) 
PDF Company to host conference call and webcast today at 8:00 a.m. EDTThe European Commission (EC) approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio® in ad [Read more]